Physician profile
Misty Bendall
NPI 1376717389
$794.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $418 · 2023: $145 · 2024: $92.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $193.41 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $164.69 | 2021-2023 | Lifevest |
| Cvrx, INC. | $136.07 | 2022-2023 | Barostim Neo System |
| Novo Nordisk INC | $128.86 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $30.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.51 | 2022-2023 | Breztri |
| Abbott Laboratories | $17.94 | 2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $16.75 | 2021 | |
| Stryker Corporation | $14.10 | 2022 | |
| Astellas Pharma US INC | $13.89 | 2022 | |
| Glaxosmithkline, LLC. | $13.64 | 2023 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $13.35 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Bendall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.